Publications
5674 Results
- Journal / Conference
- Journal of Clinical Oncology 31(20):2627-2633;
- Year
- 2013
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID23733756
- PMC
- PMC3699727
- Study Number(s)
- S0715
Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane induced neuropathy in women undergoing adjuvant breast cancer therapy
- Journal / Conference
- Contemporary Clinical Trials 34(1):1-9;
- Year
- 2013
- Research Committee(s)
- Breast
- PMID
- PMID23000081
- PMC
- PMC3525786
- Study Number(s)
- S1007
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating OncotypeDX-guided management for women with breast cancer involving lymph nodes
- Journal / Conference
- Blood 121(18):3547-3553;
- Year
- 2013
- Research Committee(s)
- Lymphoma
- PMID
- PMID23386127
- PMC
- PMC3643756
- Study Number(s)
- E2496
Plasma Epstein-Barr viral DNA as a marker of tumor response in Hodgkin lymphoma
- Journal / Conference
- Journal of Clinical Oncology 31(5):536-542;
- Year
- 2013
- Research Committee(s)
- Cancer Care Delivery and Outcomes and Comparative Effectiveness
- PMID
- PMID23295802
- PMC
- PMC3565180
Patient income level and cancer clinical trial participation
- Journal / Conference
- British Journal of Haematology 161(1):76-86;
- Year
- 2013
- Research Committee(s)
- Lymphoma
- PMID
- PMID23356491
- PMC
- PMC3906856
- Study Number(s)
- E2496
The efficacy and tolerability of ABVD and Stanford V in older hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
- Journal / Conference
- Journal of the National Cancer Institute 105(13):954-959;
- Year
- 2013
- Research Committee(s)
- Cancer Care Delivery and Multiple sites
- PMID
- PMID23776198
- PMC
- PMC3699438
Implementation of timeline reforms significantly speeds up initiation of NCI-sponsored trials
- Journal / Conference
- Journal of Thoracic Oncology 8(12):1519-1528;
- Year
- 2013
- Research Committee(s)
- Lung
- PMID
- PMID24189513
- PMC
- PMC4072123
- Study Number(s)
- S0536
Phase II trial of carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab in advanced non-small cell lung cancer: SWOG 0536
- Journal / Conference
- Clinical Cancer Research 19(23):6624-32;
- Year
- 2013
- Research Committee(s)
- Lymphoma
- PMID
- PMID24130072
- PMC
- PMC3872052
- Study Number(s)
- S0016
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-Rituximab vs CHOP + 131Iodine-Tositumomab
- Journal / Conference
- Blood 121(13):2424-2431;
- Year
- 2013
- Research Committee(s)
- Leukemia
- PMID
- PMID23325837
- PMC
- PMC3612855
- Study Number(s)
- S0106, S0112, SWOG-8600, SWOG-9031, SWOG-9034 (EST-3489) (CALGB-9120), SWOG-9333, SWOG-9500, S9617, S9918
Significance of FAB subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients
- Journal / Conference
- New England Journal of Medicine, Apr 4; 368(14):1314-1325;
- Year
- 2013
- Research Committee(s)
- Genitourinary
- PMID
- PMID23550669
- PMC
- PMC3682658
- Study Number(s)
- SWOG-9346